C12N 2320/12
In functional genomics, i.e. for the determination of gene function
Official title: in functional genomics, i.e. for the determination of gene function
C12N2320/12 (In functional genomics, i.e. for the determination of gene function) appears on 163 US grants and 410 published applications in this corpus.
Search patents in C12N- Granted patents
- 163
- Published applications
- 410
- Assignees
- 199
- Inventors
- 838
- Latest grant
- 3 Mar 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2002 | 0 | 1 |
| 2003 | 0 | 5 |
| 2004 | 0 | 8 |
| 2005 | 1 | 14 |
| 2006 | 0 | 10 |
| 2007 | 1 | 16 |
| 2008 | 1 | 11 |
| 2009 | 2 | 19 |
| 2010 | 5 | 23 |
| 2011 | 5 | 20 |
| 2012 | 17 | 31 |
| 2013 | 15 | 23 |
| 2014 | 13 | 15 |
| 2015 | 14 | 25 |
| 2016 | 8 | 13 |
| 2017 | 13 | 16 |
| 2018 | 9 | 20 |
| 2019 | 11 | 20 |
| 2020 | 5 | 16 |
| 2021 | 10 | 18 |
| 2022 | 5 | 18 |
| 2023 | 6 | 11 |
| 2024 | 10 | 24 |
| 2025 | 9 | 25 |
| 2026 | 3 | 8 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Extracellular vesicle secretion reducing agent for reducing extracellular vesicle secretion, and use of the same3 Mar 2026US 12,565,654 B2THEORIA Science Inc.
- Methods for designing guide sequences for guided nucleases10 Feb 2026US 12,548,638 B2Massachusetts Institute of Technology
- Methods and compositions for sensitization of tumor cells to immune therapy6 Jan 2026US 12,516,323 B2Regeneron Pharmaceuticals, Inc.
- Compositions and methods for high-throughput activation screening to boost T cell effector function16 Dec 2025US 12,497,611 B2Yale University
- Gene targets for T-cell-based immunotherapy18 Nov 2025US 12,473,533 B2The Regents of the University of California
- Methods and compositions for sensitization of tumor cells to immune therapy13 Aug 2026US 2026/0234625 A1Regeneron Pharmaceuticals, Inc.
- Extracellular vesicle secretion reducing agent for reducing extracellular vesicle secretion, and use of the same30 Jul 2026US 2026/0218197 A1THEORIA Science Inc.
- Methods and compositions for immune cell crispr screens25 Jun 2026US 2026/0176622 A1The Broad Institute, Inc.
- Gene activation and interference targets for exhaustion/dysfunctionresistant t cell products and uses thereof21 May 2026US 2026/0139223 A1The J. David Gladstone Institutes, a Testamentary Trust Established Under the Will of J. David Glads
- Compositions, systems, and methods for modulating t cell function9 Apr 2026US 2026/0097119 A1Tune Therapeutics, Inc.
Most cited
By later US patents
- Methods and compositions involving miRNA and miRNA inhibitor molecules171US 9,506,061 B2Asuragen, Inc. · 2016
- Methods for screening bacteria, archaea, algae, and yeast using CRISPR nucleic acids43US 10,136,649 B2North Carolina State University · 2018
- CRISPR enabled multiplexed genome engineering40US 9,982,278 B2The Regents of the University of Colorado, a body corporate · 2018
- P53 modulator and cancer target34US 8,211,635 B2Board of Regents, The University of Texas System · 2012
- Methods and compositions for RNA interference22US 8,202,846 B2Cold Spring Harbor Laboratory · 2012